Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple dose escalation study of elinzanetant in healthy Japanese female adults
jRCT2071210049Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of elinzanetant in vasomotor symptoms (3 arms), sponsored by Bayer. Primary endpoint: Treatment-emergent adverse events. Started Aug 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on jRCT2071210049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210049.